Safety evaluations of adalimumab for childhood chronic rheumatic diseases

Area of Science:

• Pediatric Rheumatology
• Immunology
• Pharmacovigilance

Background:

• Childhood rheumatic diseases (CRD) are chronic inflammatory conditions causing significant disability and healthcare costs.
• Biologic therapies, particularly adalimumab, have revolutionized CRD management, reducing childhood morbidity and long-term disability.
• Extensive pediatric experience with adalimumab necessitates a thorough review of its safety data.

Purpose of the Study:

• To review and summarize published safety data on adalimumab in pediatric patients with CRD.
• To identify and discuss the most frequent and concerning adverse events associated with adalimumab therapy.
• To compare safety findings from clinical trials with real-world evidence from registries.

Main Methods:

• Systematic review of published literature on adalimumab safety in pediatric CRD.
• Analysis of data from clinical trials and real-world observational studies.
• Focus on adverse events including infections, injection site reactions, secondary autoimmune diseases, and malignancy.

Main Results:

• Adalimumab demonstrates a highly acceptable safety profile, revolutionizing CRD treatment and prognosis.
• Infections and injection site reactions are common adverse events.
• Concerns regarding secondary autoimmune diseases and malignancy require ongoing monitoring.

Conclusions:

• Adalimumab offers significant benefits for children with CRD, with a generally favorable safety profile.
• Discrepancies in adverse event reporting exist between clinical trials and real-world registries.
• Complementary data from randomized clinical trials and long-term registries are essential for improving evidence-based safety in pediatric CRD treatment.